News | December 07, 2025
Takeda seals $1.2 billion oncology deal with Innovent Biologics
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Innovent will supply sintilimab for the collaborated clinical trial
LG Chem will receive totaling up to $95.5 million for the China rights
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Subscribe To Our Newsletter & Stay Updated
